Claims
- 1. A method of inhibiting the growth of a neoplastic cell, the method comprising contacting the cell with a chemotherapeutic drug and a ZNF217 inhibitor, thereby inhibiting the growth of the neoplastic cell.
- 2. The method of claim 1, wherein the ZNF217 inhibitor comprises an antisense nucleic acid.
- 3. The method of claim 1, wherein the ZNF217 inhibitor comprises an siRNA nucleic acid.
- 4. The method of claim 1, wherein the chemotherapeutic drug is a topoisomerase inhibitor.
- 5. The method of claim 1, wherein the chemotherapeutic drug is doxorubicin.
- 6. The method of claim 1, wherein the chemotherapeutic drug activates apoptotic pathways.
- 7. A method of potentiating antineoplastic therapy in a patient, the method comprising the steps of:
(a) administering a ZNF217 inhibitor to the patient; and (b) administering an antineoplastic therapy to the patient, thereby potentiating antineoplastic therapy in the patient.
- 8. The method of claim 7, wherein the ZNF217 inhibitor comprises an siRNA nucleic acid.
- 9. The method of claim 7, wherein the ZNF217 inhibitor comprises an antisense nucleic acid.
- 10. The method of claim 7, wherein the antineoplastic therapy comprises administering radiation to the patient.
- 11. The method of claim 7, wherein the antineoplastic therapy comprises administering a chemotherapeutic drug to the patient.
- 12. A method of identifying agents that promote cell death in a mammalian cell, the method comprising the steps of:
(a) providing a mammalian cell engineered to overexpress ZNF217; (b) contacting the cell with a test agent; and (c) assaying for the effect of the test agent on death of the cell, thereby identifying agents that promote death in a mammalian cell.
- 13. The method of claim 12, further comprising the step of contacting the cell with a chemotherapeutic drug.
- 14. The method of claim 13, wherein the chemotherapeutic drug is a drug that promotes apoptosis.
- 15. The method of claim 13, wherein the chemotherapeutic drug is a topoisomerase inhibitor.
- 16. The method of claim 12, wherein the effect of the test agent on death of the cell is assayed by measuring the incidence of apoptosis.
- 17. The method of claim 12, wherein the effect of the test agent on death of the cell is assayed by measuring the activity of p53.
- 18. The method of claim 12, wherein the cell is transfected with a nucleic acid construct encoding ZNF217.
- 19. The method of claim 12, wherein the cell is in culture.
- 20. The method of claim 12, wherein the cell is in a mouse.
- 21. A method of identifying a compound that modulates activity of a ZNF217 polypeptide, the method comprising the steps of:
(a) contacting the ZNF217 polypeptide with the compound, wherein the ZNF217 polypeptide comprises at least 85% amino acid sequence identity to the amino acid sequence of ZNF217 (GenBank Accession No. AAC39895; RefSeq Accession ID No. NP—006517); and (b) determining the functional effect of the compound on the ZNF217 polypeptide thereby identifying a compound that modulates activity of ZNF217 polypeptide.
- 22. The method of claim 21, wherein the polypeptide is linked to a solid phase.
- 23. The method of claim 22, wherein the polypeptide is covalently linked to a solid phase.
- 24. The method of claim 21, wherein the polypeptide is expressed in a cell.
- 25. The method of claim 24, wherein the polypeptide is amplified in the cell compared to normal.
- 26. The method of claim 21, wherein the polypeptide has an amino acid sequence
- 27. A method of identifying agents that modulate the activity of a chemotherapeutic drug, the method comprising the steps of:
(a) providing a mammalian cell engineered to overexpress ZNF217; (b) contacting the cell with a test agent and a chemotherapeutic drug; and (c) assaying for the effect of the test agent on the activity of the chemotherapeutic drug, thereby identifying agents that modulate the activity of the chemotherapeutic drug.
- 28. The method of claim 27, wherein the chemotherapeutic drug is a topoisomerase inhibitor.
- 29. The method of claim 28, wherein the chemotherapeutic drug is doxorubicin.
- 30. A method of monitoring the efficacy of a cancer treatment, the method comprising detecting the level of a ZNF217 polypeptide or polynucleotide in a biological sample from a patent undergoing treatment for cancer, wherein a reduced level of the ZNF217 polypeptide or polynucleotide in the biological sample compared to the level in a biological sample from the patient prior to, or earlier in, the treatment is indicative of efficacious treatment.
- 31. The method of claim 30, wherein the cancer is breast cancer.
- 32. The method of claim 30, wherein the patient is a human.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] The present application claims benefit of priority to U.S. Provisional Patent Application No. 60/351,530, filed on Jan. 22, 2002, which is incorporated in its entirety for all purposes.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60351530 |
Jan 2002 |
US |